Erasca Hit With Securities Class Action After $2.8B Market Cap Loss
A securities fraud lawsuit alleges Erasca misled investors about IP and drug safety, triggering a 48% stock drop. Investors have until August 10, 2026 to seek lead plaintiff status.
ERAS-0015
ProductLast mentioned: 3d ago
Timeline
-
Lead Plaintiff Deadline
Deadline for investors to move for appointment as lead plaintiff in the securities class action.
-
Securities Class Action Announced
Hagens Berman announces the filing of a federal securities class action lawsuit and begins soliciting investor clients.
-
Stock Crash and Corrective Disclosure
Erasca shares plunge 48% on news that Revolution Medicines accused the company of patent infringement and that a trial patient died a month after receiving ERAS-0015. Class period ends.
-
Alleged Misleading Statements
Erasca reportedly assured investors of ERAS-0015's IP protection and made dose-equivalence comparisons to RevMed's RMC-6236.
-
Class Period Begins
Start of the period during which Erasca allegedly made misleading statements that inflated its stock price.
Stories mentioning ERAS-0015 1
About ERAS-0015 coverage
This page surfaces every story mentioning ERAS-0015 across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where ERAS-0015 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |